| AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations Y Yuan, L Zhou, T Miyamoto, H Iwasaki, N Harakawa, CJ Hetherington, ... Proceedings of the National Academy of Sciences 98 (18), 10398-10403, 2001 | 536 | 2001 |
| Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation SA Burel, N Harakawa, L Zhou, T Pabst, DG Tenen, DE Zhang Molecular and cellular biology 21 (16), 5577-5590, 2001 | 192 | 2001 |
| Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts SA Burel, CE Hart, P Cauntay, J Hsiao, T Machemer, M Katz, A Watt, ... Nucleic acids research 44 (5), 2093-2109, 2016 | 181 | 2016 |
| Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development M Yan, SA Burel, LF Peterson, E Kanbe, H Iwasaki, A Boyapati, R Hines, ... Proceedings of the National Academy of Sciences 101 (49), 17186-17191, 2004 | 171 | 2004 |
| Comprehensive Structure–Activity Relationship of Triantennary N-Acetylgalactosamine Conjugated Antisense Oligonucleotides for Targeted Delivery to Hepatocytes TP Prakash, J Yu, MT Migawa, GA Kinberger, WB Wan, ME Østergaard, ... Journal of medicinal chemistry 59 (6), 2718-2733, 2016 | 133 | 2016 |
| Non-CpG-containing antisense 2′-methoxyethyl oligonucleotides activate a proinflammatory response independent of Toll-like receptor 9 or myeloid differentiation factor 88 JJ Senn, S Burel, SP Henry Journal of Pharmacology and Experimental Therapeutics 314 (3), 972-979, 2005 | 121 | 2005 |
| Integrated safety assessment of 2′-O-methoxyethyl chimeric antisense oligonucleotides in nonhuman primates and healthy human volunteers ST Crooke, BF Baker, TJ Kwoh, W Cheng, DJ Schulz, S Xia, N Salgado, ... Molecular Therapy 24 (10), 1771-1782, 2016 | 112 | 2016 |
| Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound targeting signal transducer and activator of transcription 3 in … SA Burel, SR Han, HS Lee, DA Norris, BS Lee, T Machemer, SY Park, ... Nucleic acid therapeutics 23 (3), 213-227, 2013 | 91 | 2013 |
| Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data NJ Viney, S Guo, LJ Tai, BF Baker, M Aghajan, SW Jung, RZ Yu, S Booten, ... ESC heart failure 8 (1), 652-661, 2021 | 78 | 2021 |
| Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides BA Anderson, GC Freestone, A Low, CL De-Hoyos, WJD Iii, ... Nucleic Acids Research 49 (16), 9026-9041, 2021 | 75 | 2021 |
| Investigation into the mechanism (s) that leads to platelet decreases in cynomolgus monkeys during administration of ISIS 104838, a 2-MOE-modified antisense oligonucleotide P Narayanan, L Shen, BR Curtis, MA Bourdon, JP Nolan, S Gupta, ... Toxicological Sciences 164 (2), 613-626, 2018 | 38 | 2018 |
| Unique O-methoxyethyl ribose-DNA chimeric oligonucleotide induces an atypical melanoma differentiation-associated gene 5-dependent induction of type I interferon response SA Burel, T Machemer, FL Ragone, H Kato, P Cauntay, S Greenlee, ... Journal of Pharmacology and Experimental Therapeutics 342 (1), 150-162, 2012 | 30 | 2012 |
| Assessment of the effects of 2′-methoxyethyl antisense oligonucleotides on platelet count in cynomolgus nonhuman primates SP Henry, P Narayanan, L Shen, S Bhanot, HS Younis, SA Burel nucleic acid therapeutics 27 (4), 197-208, 2017 | 29 | 2017 |
| Underlying immune disorder may predispose some transthyretin amyloidosis subjects to inotersen-mediated thrombocytopenia PK Narayanan, BR Curtis, L Shen, E Schneider, JA Tami, S Paz, SA Burel, ... nucleic acid therapeutics 30 (2), 94-103, 2020 | 27 | 2020 |
| The Distinct and Cooperative Roles of Toll-Like Receptor 9 and Receptor for Advanced Glycation End Products in Modulating In Vivo Inflammatory Responses to … S Paz, J Hsiao, P Cauntay, A Soriano, L Bai, T Machemer, X Xiao, S Guo, ... nucleic acid therapeutics 27 (5), 272-284, 2017 | 25 | 2017 |
| Early-stage identification and avoidance of antisense oligonucleotides causing species-specific inflammatory responses in human volunteer peripheral blood mononuclear cells SA Burel, T Machemer, BF Baker, TJ Kwoh, S Paz, H Younis, SP Henry nucleic acid therapeutics 32 (6), 457-472, 2022 | 10 | 2022 |
| Safety, Pharmacokinetic, and Pharmacodynamic Evaluation of a 2′-(2-Methoxyethyl)-D-ribose Antisense Oligonucleotide–Triantenarry N-Acetyl-galactosamine Conjugate that Targets … TA Zanardi, B Korbmacher, L Boone, JA Engelhardt, Y Wang, S Burel, ... Journal of Pharmacology and Experimental Therapeutics 377 (1), 51-63, 2021 | 8 | 2021 |
| Inflammatory non-CpG antisense oligonucleotides are signaling through TLR9 in human Burkitt lymphoma B Bjab cells AJ Pollak, P Cauntay, T Machemer, S Paz, S Damle, SP Henry, SA Burel Nucleic acid therapeutics 32 (6), 473-485, 2022 | 5 | 2022 |
| Hybrid mouse diversity panel identifies genetic architecture associated with the acute antisense oligonucleotide-mediated inflammatory response to a 2′-O-Methoxyethyl … E Pirie, P Cauntay, W Fu, S Ray, C Pan, AJ Lusis, J Hsiao, SA Burel, ... nucleic acid therapeutics 29 (5), 266-277, 2019 | 4 | 2019 |
| AML1 and AML1 fusion protein AML1-ETO in myeloid gene regulation and leukemogenesis DE Zhang, S Burel, L Zhou, CJ Hetherington, Y Yuan Blood Cells, Molecules, and Diseases 27 (2), 368-376, 2001 | 4 | 2001 |
